UNCY FY2026 EPS Increased by Brookline Capital Management

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Brookline Capital Management boosted their FY2026 earnings estimates for shares of Unicycive Therapeutics in a report issued on Wednesday, November 13th. Brookline Capital Management analyst K. Raja now expects that the company will post earnings per share of $1.88 for the year, up from their previous estimate of $1.85. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.26) per share. Brookline Capital Management also issued estimates for Unicycive Therapeutics’ FY2027 earnings at $2.58 EPS and FY2028 earnings at $1.37 EPS.

Other research analysts have also recently issued research reports about the company. Benchmark reaffirmed a “speculative buy” rating and issued a $3.00 price target on shares of Unicycive Therapeutics in a report on Friday, September 6th. HC Wainwright reaffirmed a “buy” rating and issued a $2.50 price target on shares of Unicycive Therapeutics in a research note on Tuesday, November 12th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $5.13.

Unicycive Therapeutics Price Performance

UNCY opened at $0.46 on Friday. The business has a 50 day moving average price of $0.43 and a two-hundred day moving average price of $0.55. The company has a market capitalization of $43.40 million, a price-to-earnings ratio of -0.47 and a beta of 2.29. Unicycive Therapeutics has a 1-year low of $0.20 and a 1-year high of $1.82.

Unicycive Therapeutics (NASDAQ:UNCY) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.08.

Hedge Funds Weigh In On Unicycive Therapeutics

Large investors have recently made changes to their positions in the business. XTX Topco Ltd bought a new stake in Unicycive Therapeutics in the 3rd quarter valued at $29,000. Bleakley Financial Group LLC bought a new stake in Unicycive Therapeutics in the 3rd quarter valued at $33,000. Virtu Financial LLC bought a new stake in Unicycive Therapeutics in the first quarter valued at about $36,000. Acuta Capital Partners LLC bought a new position in Unicycive Therapeutics during the third quarter worth about $807,000. Finally, Walleye Capital LLC acquired a new stake in Unicycive Therapeutics during the third quarter valued at approximately $2,040,000. Institutional investors and hedge funds own 40.42% of the company’s stock.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.